- Home
- TTGT vs TRDA Comparison
TTGT vs TRDA Comparison
Compare TTGT & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTGT
- TRDA
- Stock Information
- Founded
- TTGT 1999
- TRDA 2016
- Country
- TTGT United States
- TRDA United States
- Employees
- TTGT N/A
- TRDA N/A
- Industry
- TTGT Telecommunications Equipment
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- TTGT Telecommunications
- TRDA Health Care
- Exchange
- TTGT Nasdaq
- TRDA Nasdaq
- Market Cap
- TTGT 352.9M
- TRDA 386.8M
- IPO Year
- TTGT 2007
- TRDA 2021
- Fundamental
- Price
- TTGT $5.22
- TRDA $10.22
- Analyst Decision
- TTGT Strong Buy
- TRDA Strong Buy
- Analyst Count
- TTGT 4
- TRDA 2
- Target Price
- TTGT $11.25
- TRDA $24.50
- AVG Volume (30 Days)
- TTGT 509.1K
- TRDA 298.8K
- Earning Date
- TTGT 11-10-2025
- TRDA 11-06-2025
- Dividend Yield
- TTGT N/A
- TRDA N/A
- EPS Growth
- TTGT N/A
- TRDA N/A
- EPS
- TTGT N/A
- TRDA N/A
- Revenue
- TTGT $446,514,000.00
- TRDA $61,520,000.00
- Revenue This Year
- TTGT $73.47
- TRDA N/A
- Revenue Next Year
- TTGT $3.95
- TRDA N/A
- P/E Ratio
- TTGT N/A
- TRDA N/A
- Revenue Growth
- TTGT 71.55
- TRDA N/A
- 52 Week Low
- TTGT $4.63
- TRDA $4.93
- 52 Week High
- TTGT $33.96
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- TTGT 49.58
- TRDA 78.19
- Support Level
- TTGT $4.65
- TRDA $8.17
- Resistance Level
- TTGT $5.22
- TRDA $10.75
- Average True Range (ATR)
- TTGT 0.34
- TRDA 0.67
- MACD
- TTGT 0.04
- TRDA 0.16
- Stochastic Oscillator
- TTGT 46.69
- TRDA 87.24
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.